Preventing low white blood cells during chemo-radiation for chest cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if a study drug (Thiopegfilgrastim) can help prevent a dangerous drop in white blood cells (bone marrow suppression) in people with esophageal or lung cancer who are getting chemo and radiation. It may reduce your risk of infection during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with lung cancer or esophageal cancer
- Your doctor plans to give you chemo and radiation at the same time
- Your chemo regimen has at least a 20% risk of causing a fever with low white blood cells, or a 10-20% risk if you have other risk factors
- You are expected to live more than 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares different doses of a medication called PEG-rhG-CSF, which is used to help prevent a serious side effect of chemotherapy called febrile neutropenia (fever with a low white blood cell count). The goal is to find the best dose that keeps your blood counts healthy and reduces the risk of infection during treatment.
This trial tests giving a combination of immunotherapy, a growth factor to boost white blood cells, and chemotherapy before surgery for stomach cancer. The goal is to shrink the tumor and improve surgical outcomes.
This study tests a drug (me capegfilgrastim) given as a shot to help prevent a dangerous drop in white blood cells and fever during chemotherapy. It is for people with cancer who are at high risk for this side effect.
This trial tests a medication that aims to reduce the risk of dangerously low white blood cell counts (neutropenia) after chemotherapy combined with immunotherapy for certain advanced lung or esophageal cancers. It may help prevent infections and other complications, making treatment safer.
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
Hear when a new Myelosuppression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.